Pirfenidone Attenuates Cardiac Fibrosis in a Mouse Model of TAC-Induced Left Ventricular Remodeling by Suppressing NLRP3 Inflammasome Formation

No abstract is available for this paper.

• Publication year

  2013

• Venue

  The Cardiology

• Publication date

  2013-07-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000351179PMID 23839341
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inflammasomes in wound healing and fibrosis

  2013cited by this paper
• Priming with synthetic oligonucleotides attenuates pressure overload-induced inflammation and cardiac hypertrophy in mice.

  2012cited by this paper
• Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy.

  2012cited by this paper
• Aldosterone Inhibits the Fetal Program and Increases Hypertrophy in the Heart of Hypertensive Mice

  2012cited by this paper
• The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice

  2012cited by this paper
• Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function

  2012cited by this paper
• Regulation of inflammasome signaling

  2012cited by this paper
• Nebivolol prevents myocardial fibrosis and diastolic dysfunction in salt-loaded spontaneously hypertensive rats.

  2012cited by this paper
• Development and psychometric evaluation of the Treatment Adherence Questionnaire for Patients with Hypertension.

  2012cited by this paper
• Inflammasomes in health and disease

  2012cited by this paper
• Pirfenidone

  2011cited by this paper
• Pirfenidone for diabetic nephropathy.

  2011cited by this paper
• In Vitro Effects of Pirfenidone on Cardiac Fibroblasts: Proliferation, Myofibroblast Differentiation, Migration and Cytokine Secretion

  2011cited by this paper
• Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy.

  2011cited by this paper
• The Plk1 Inhibitor BI 2536 Temporarily Arrests Primary Cardiac Fibroblasts in Mitosis and Generates Aneuploidy In Vitro

  2010cited by this paper
• NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?

  2010cited by this paper
• Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy.

  2010cited by this paper
• The NALP3/NLRP3 Inflammasome Instigates Obesity-Induced Autoinflammation and Insulin Resistance

  2010cited by this paper
• Cardiomyocyte preparation, culture, and gene transfer.

  2007cited by this paper
• Pirfenidone effectively reverses experimental liver fibrosis.

  2002cited by this paper

• Intravesical instillation of pirfenidone/polydopamine nanoparticles for managing neurogenic bladder post-spinal cord injury by alleviating bladder inflammation and fibrosis

  2026cites this paper
• Pirfenidone ameliorates dexamethasone-induced steatohepatitis and vascular resistance in rats.

  2026cites this paper
• Current Application of Mineralocorticoid Antagonist (MRA) in Heart Failure and CKD: Does Non-Steroidal Drug Add Novel Insights

  2025cites this paper
• Advances in Cardiac Fibrosis Research and Treatment Development

  2025cites this paper
• PCSK9 Enhances Cardiac Fibrogenesis via the Activation of Toll-like Receptor and NLRP3 Inflammasome Signaling

  2025cites this paper
• Novel Interleukin-11 Inhibitors Attenuate Collagen Production in Patient-Derived Synovial Fibroblasts

  2025cites this paper
• Targeting inhibition of the inflammatory response: advances in the treatment of myocardial fibrosis with natural medicine and active ingredients

  2025cites this paper
• Multiorgan characterization of inflammasome component expression in a rat model of advanced heart failure

  2025cites this paper
• Pirfenidone use in fibrotic diseases: What do we know so far?

  2024cites this paper
• CYP1A2 Polymorphism and Drug Co-administration Affect the Blood Levels and Adverse Effects of Pirfenidone

  2024cites this paper
• Fibroblasts and platelets, a face-to-face dialogue at the heart of cardiac fibrosis.

  2024cites this paper
• Current experimental and early investigational agents for cardiac fibrosis: where are we at?

  2024cites this paper
• Exploring in vivo and in vitro models for heart failure with biomarker insights: a review

  2024cites this paper
• The Tan-Re-Qing Capsule mitigates acute lung injury by suppressing the NLRP3 inflammasome and MAPK/NF-κB signaling pathways.

  2024cites this paper
• Application of Compounds with Anti‐Cardiac Fibrosis Activity: A Review

  2024cites this paper
• At the heart of inflammation: Unravelling cardiac resident macrophage biology

  2024cites this paper
• Zebrafish as an innovative model for exploring cardiovascular disease induction mechanisms and novel therapeutic interventions: a molecular insight

  2024cites this paper
• Evaluation of N-terminal pro-atrial natriuretic peptide and Soluble ST2 as Predictors for Cardiovascular Diseases in Patients with Type 2 Diabetes in Al-Basra, Iraq

  2024cites this paper
• Pirfenidone Prevents Heart Fibrosis during Chronic Chagas Disease Cardiomyopathy

  2024cites this paper
• Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis

  2023cites this paper
• Signaling Pathways and Potential Therapeutic Strategies in Cardiac Fibrosis

  2023cites this paper
• Deciphering the Role of Pyroptosis Impact on Cardiovascular Diseases.

  2023cites this paper
• Axitinib targets cardiac fibrosis in pressure overload-induced heart failure through VEGFA-KDR pathway

  2023cites this paper
• Aging and atrial fibrillation: A vicious circle.

  2023cites this paper
• Research progress on the activation mechanism of NLRP3 inflammasome in septic cardiomyopathy

  2023influential citation
• Fluorofenidone enhances cardiac contractility by stimulating CICR and CaV1.2.

  2023cites this paper
• Targeting the NLRP3 inflammasome for the treatment of hypertensive target organ damage: Role of natural products and formulations

  2023cites this paper
• Literature Review: Pathophysiology of Heart Failure with Preserved Ejection Fraction.

  2023cites this paper
• Drugs Targeting NLRP3 Inflammasome in the Treatment of Diabetic Bone Disorders.

  2023cites this paper
• Pirfenidone affects human cardiac fibroblast proliferation and cell cycle activity in 2D cultures and engineered connective tissues

  2023cites this paper
• Repositioning Glibenclamide in cardiac fibrosis by targeting TGF-β1-pSmad2/3-NLRP3 cascade

  2023cites this paper
• Pirfenidone ameliorates pulmonary arterial pressure and neointimal remodeling in experimental pulmonary arterial hypertension by suppressing NLRP3 inflammasome activation

  2022cites this paper
• Modulation of subsets of cardiac B lymphocytes improves cardiac function after acute injury

  2022cites this paper
• NLRP3 Inflammasome Activation Through Heart-Brain Interaction Initiates Cardiac Inflammation and Hypertrophy During Pressure Overload

  2022cites this paper
• Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy

  2022cites this paper
• The human myocardium harbors a population of naive B-cells with a distinctive gene expression signature conserved across species

  2022cites this paper
• Pirfenidone alleviates cardiac fibrosis induced by pressure overload via inhibiting TGF‐β1/Smad3 signalling pathway

  2022cites this paper
• Silencing of TLR4 Inhibits Atrial Fibrosis and Susceptibility to Atrial Fibrillation via Downregulation of NLRP3-TGF-β in Spontaneously Hypertensive Rats

  2022cites this paper
• NLRP3 Inflammasome: a Novel Insight into Heart Failure

  2022cites this paper
• Fibrotic Signaling in Cardiac Fibroblasts and Vascular Smooth Muscle Cells: The Dual Roles of Fibrosis in HFpEF and CAD

  2022cites this paper
• Pyroptosis: Role and Mechanisms in Cardiovascular Disease

  2022cites this paper
• Cardiac Fibrosis in the Pressure Overloaded Left and Right Ventricle as a Therapeutic Target

  2022cites this paper
• The Mechanism and Regulation of the NLRP3 Inflammasome during Fibrosis

  2022cites this paper
• Pirfenidone prevents esophageal stricture by inhibiting nucleotide binding oligomerization domain like receptor protein 3 inflammasome activation

  2022cites this paper
• Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond

  2022cites this paper
• Emerging Roles of Inflammasomes in Cardiovascular Diseases

  2022cites this paper
• Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis

  2022cites this paper
• Long and narrow road to win over myocardial ischemia-reperfusion injury.

  2022cites this paper
• The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease

  2022cites this paper
• Ranolazine Inhibits Pyroptosis via Regulation of miR-135b in the Treatment of Diabetic Cardiac Fibrosis

  2022cites this paper
• Commentary: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused

  2021cites this paper
• NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications

  2021cites this paper
• Targeting the NLRP3 inflammasome in cardiovascular diseases.

  2021cites this paper
• Targeting the Inflammasome in Cardiovascular Disease

  2021cites this paper
• Pirfenidone as a novel cardiac protective treatment

  2021cites this paper
• Attenuation of Myocardial Fibrosis Using Molecular Hydrogen by Inhibiting the TGF-β Signaling Pathway in Spontaneous Hypertensive Rats.

  2021cites this paper
• Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial

  2021cites this paper
• Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation

  2021cites this paper
• Molecular Basis of Atrial Fibrillation Initiation and Maintenance

  2021cites this paper
• Inflammasome Activation-Induced Hypercoagulopathy: Impact on Cardiovascular Dysfunction Triggered in COVID-19 Patients

  2021influential citation
• Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction

  2021cites this paper
• NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases

  2021cites this paper
• Effects of Pirfenidone on Echocardiographic Parameters of Left Ventricular Structure and Function in Patients with Idiopathic Pulmonary Fibrosis

  2020cites this paper
• Pirfenidone is a Cardioprotective Drug: Mechanisms of Action and Preclinical Evidence.

  2020cites this paper
• Inflammasomes—A Molecular Link for Altered Immunoregulation and Inflammation Mediated Vascular Dysfunction in Preeclampsia

  2020cites this paper
• Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis.

  2020cites this paper
• NLRP3 Inflammasome and Inflammatory Diseases

  2020cites this paper
• Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling

  2020cites this paper
• Isoproterenol Increases Left Atrial Fibrosis and Susceptibility to Atrial Fibrillation by Inducing Atrial Ischemic Infarction in Rats

  2020cites this paper
• Electroacupuncture preconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting mitophagy mediated by the mTORC1-ULK1-FUNDC1 pathway.

  2020cites this paper
• Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

  2020cites this paper
• NLRP3 inflammasome, an immune‐inflammatory target in pathogenesis and treatment of cardiovascular diseases

  2020cites this paper
• Insight into the Pro-inflammatory and Pro-Fibrotic Role of Macrophage in Heart Failure with Preserved Ejection Fraction.

  2020cites this paper
• Pirfenidone: A novel hypothetical treatment for COVID-19

  2020cites this paper
• N-acetylcysteine alleviates post-resuscitation myocardial dysfunction and improves survival outcomes via partly inhibiting NLRP3 inflammasome induced-pyroptosis

  2020cites this paper
• Pathophysiology of Atrial Fibrillation and Chronic Kidney Disease.

  2020cites this paper
• Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?

  2020cites this paper
• Pirfenidone attenuates gentamicin-induced acute kidney injury by inhibiting inflammasome-dependent NLRP3 pathway in rats.

  2020cites this paper
• Pirfenidone and Vitamin D Ameliorate Cardiac Fibrosis Induced by Doxorubicin in Ehrlich Ascites Carcinoma Bearing Mice: Modulation of Monocyte Chemoattractant Protein-1 and Jun N-terminal Kinase-1 Pathways

  2020cites this paper
• Role of IgE-FcεR1 in Pathological Cardiac Remodeling and Dysfunction.

  2020cites this paper
• Controlling cardiac fibrosis through fibroblast state space modulation.

  2020cites this paper
• Effects of Pirfenidone on Echocardiographic Parameters of Left Ventricular Structure and Function in Patients with Idiopathic Pulmonary Fibrosis

  2020cites this paper
• Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction

  2019cites this paper
• Human cardiac fibrosis-on-a-chip model recapitulates disease hallmarks and can serve as a platform for drug testing.

  2019cites this paper
• Key Cellular Effectors in ROS-Mediated Cardiac Diseases

  2019cites this paper
• Serelaxin inhibits the profibrotic TGF‐β1/IL‐1β axis by targeting TLR‐4 and the NLRP3 inflammasome in cardiac myofibroblasts

  2019cites this paper
• Inflammation in non-ischemic heart disease: initiation by cardiomyocyte CaMKII and NLRP3 inflammasome signaling.

  2019cites this paper
• Regulatory Mechanisms of the NLRP3 Inflammasome, a Novel Immune-Inflammatory Marker in Cardiovascular Diseases

  2019cites this paper
• BAOXIN Granules Protected Mouse Model With Elevated Afterload From Cardiac Hypertrophy by Suppressing Both Inflammatory Reaction and Collagen Deposition

  2019cites this paper
• Role of Pyroptosis in Cardiovascular Diseases and its Therapeutic Implications

  2019cites this paper
• Human cardiac fibrosis-on-a-chip model recapitulates disease hallmarks and can serve as a platform for drug screening

  2019cites this paper
• Pirfenidone in Heart Failure with Preserved Ejection Fraction—Rationale and Design of the PIROUETTE Trial

  2019cites this paper
• Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone

  2019cites this paper
• Cardiac fibrosis: potential therapeutic targets.

  2019cites this paper
• Hydrogen sulfide-mediated regulation of cell death signaling ameliorates adverse cardiac remodeling and diabetic cardiomyopathy.

  2019cites this paper
• Mast Cells in Cardiac Fibrosis: New Insights Suggest Opportunities for Intervention

  2019cites this paper
• Curcumin Management of Myocardial Fibrosis and its Mechanisms of Action: A Review.

  2019cites this paper
• Disconnect between Fibrotic Response and Right Ventricular Dysfunction.

  2019cites this paper
• Antifibrotic Agent Pirfenidone Protects against Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model

  2018cites this paper
• Sulforaphane, a Natural Isothiocyanate Compound, Improves Cardiac Function and Remodeling by Inhibiting Oxidative Stress and Inflammation in a Rabbit Model of Chronic Heart Failure

  2018cites this paper